Here’s What to Expect From Regeneron Pharmaceuticals’ Next Earnings Report

Regeneron Pharmaceuticals, a biotechnology firm with a market capitalization of $68.8 billion headquartered in Tarrytown, New York, develops antibody-based treatments for serious diseases. The company is scheduled to release its second-quarter 2026 earnings results before market open on July 30.
Analysts anticipate the company will report earnings per share of $8, representing a 25.4% decline from the prior-year quarter’s $10.72 per share. However, Regeneron has maintained a track record